I began using Motley Fool’s CAPS as a way to disclose when I purchased and sold stocks, and my 97.2 rating showcases my last 10 months. CAPS compares your performance against other investors, but like all investments, you have to continuously reassess your positions. In this article, I am looking at my top four CAPS (portfolio) performers to determine if any are now a “Sell”.
Could There Be more »
Questcor Pharmaceuticals (NASDAQ: QCOR) reported earnings after the bell on Tuesday and traded significantly higher. The stock is now up more than 215% since its October 2012 low. Now, with the stock touching new all-time highs, it is in uncharted territory, but is it still cheap compared to its closest peer?
Two companies/Same approach
Despite some negative news, mainly related to reimbursement issues and excess stock booking, Questcor Pharmaceuticals (NASDAQ: QCOR) recently gained solid momentum due to a couple of factors.
One was the sales growth of Acthar Gel and the addition of BioVectra sales during Q1 2013. The other was the announcement of acquiring exclusive rights of Synacthen from Novartis. Both facts together made the stock go up 15% and more last week more »
Note: This article has been amended to remove the specifics of the Questcor investigation. Motley Fool apologizes for the error.
Celgene (NASDAQ: CELG) fell 2.6% on Thursday after disappointing clinical data for its blood cancer drug Revlimid. Investors don’t appear too concerned, but I believe this news could be more crippling than the stock’s reaction suggests.
What Is Revlimid?
Revlimid is already approved to treat multiple myeloma more »
Questcor Pharmaceuticals (NASDAQ: QCOR) has a particularly fascinating history, having been at the center of controversy for the better part of its existence. For several years, investors have enjoyed large returns, and the company has marketed its only product, Acthar, with exceptional success. As it approaches new highs, should you take notice?
The Center of Controversy
Questcor Pharmaceuticals markets and develops Acthar Gel. It's a treatment for infantile spasms more »
For the last several years, certain stocks have remained cheap as the overwhelming presence of short sellers have made it more difficult for shares to break out. On July 4, Bespoke Investment Group’s list of the most heavily shorted S&P 500 stocks was released, showing data as of June 15. A comparison of data from late February shows that short sellers might finally be leaving some of the more »
Opportunities often come with a degree of ambiguity and it is mostly difficult to tell cheese from chalk. Questcor (NASDAQ: QCOR), Lululemon Athletica (NASDAQ: LULU), and Bazaarvoice (NASDAQ: BV) are three examples. Here is some sense out of the noise:
Questcor’s Shares Surged After New Drug Development
Shares of California based specialty biopharmaceutical company Questcor surged after it announced an agreement with Novartis to develop anti-inflammatory Synacthen and more »
Questcor Pharmaceuticals (NASDAQ: QCOR) saw a 15% gain on Tuesday. The large gains occurred after the company acquired rights to develop the autoimmune drug Synacthen in the U.S. from Novartis for $60 million upfront and $75 million in milestone payments. In addition, Questcor will have to pay Novartis a royalty on sales; if it’s approved in the U.S.
Last November, Synacthen was awarded Orphan designation by the more »
Virtually every investor is quite familiar with the names of big pharmaceutical giants such as Glaxosmithkline, Eli Lilly, and Abbott Labs and the fortunes that have been made by investors in these enormously successful businesses. What many investors fail to spend time considering is that a much of the growth of these large businesses came from buyouts of smaller faster growing companies within the pharmaceutical industry that were priced cheaply more »
Questcor Pharmaceuticals, Inc. (Questcor), incorporated November 02, 1990, is an integrated specialty pharmaceutical company focused on the development, acquisition and marketing of innovative, acute care and critical care hospital/specialty pharmaceutical products. The Company is focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders.The company's primary product is H.P. Acthar Gel, an injectable drug used for the treatment of 19 indications including more »
When you look at the S&P 500’s most shorted stocks, all are cheap yet short investors continue to bet on lower prices. Therefore, I am looking at the most shorted stocks according to Bespoke Investment Group’s monthly list, to determine if any are a “buy.”
Short-Interest vs. Float
Shares Short (4/30)
Shares Short (3/30)
Blyth (NYSE: BTH)
5.32 more »
Questcor Pharmaceuticals (NASDAQ: QCOR) has faced the affects of bad press more than once in the past. The stock lost more than half of its value last year, after reports about its questionable marketing practices spurred a federal investigation. While that drop was extremely painful for long-term investors, it gave speculators and short-term traders an opportunity to make substantial profits, and let long-term investors add to their positions. The stock more »
With earnings season in full-swing, and with countless large moving stocks, I am looking at four companies that reported earnings on Wednesday that I believe are a “buy,” regardless of the stock’s initial reaction.
An Under-the-Radar Stock to Watch
Mueller Water Products (NYSE: MWA) saw gains of more than 13% after the company announced earnings that handily beat expectations. The company experienced sales growth of 12.6% year-over-year (yoy more »
Many believed that Q1 earnings would be the start of a larger trend higher that reversed the losses seen in shares of Questcor Pharmaceuticals (NASDAQ: QCOR) over the last year, but were those people ever wrong.
Questcor Pharmaceuticals is trading with losses of 9% immediately following its Q1 earnings report. For the quarter, Questcor grew 41% and posted revenue of $135 million and an EPS of $0.76 more »
The market for prescription and over-the-counter drugs is huge and hugely profitable. With the global trend of an aging population well underway, it is nearly inevitable that demand for prescription and non-prescription drugs will rise. While much is made in the media regarding the so-called “patent cliff” faced by the large drug makers, well-placed investments now will allow investors to reap double-digit gains for years to come. Investors who are more »
Have you ever been dumpster diving? I have--it is a great past time. One thing I've learned is that you never know what some people will throw away. Sometimes there is a reason it is being thrown out, while other times you find something that proves the old adage: one man's trash is another man's treasure.
This applies to the stock market as well. Many an investor more »
To say that William Leland Edwards of Palo Alto Investors invests heavily in healthcare stocks would be, well, a bit of an understatement. The fund’s positions read like a pharmaceutical sales rep’s resume, with the top five positions, more than 50% of the entire portfolio, all coming from the biopharmaceutical sector. Mr. Edwards has no medical training and does not hold a degree in biology or chemistry. But more »
Have you ever been dumpster diving? I have. It is a great past time. One thing I've learned is that you never know what some people will throw away. Sometimes there is a reason it is being thrown out. Other times you find something that proves the old adage: one man's trash is another man's treasure.
This applies to the stock market as well. Many an investor more »
To say that William Leland Edwards of Palo Alto Investors invest heavily in healthcare stocks would be, well, a bit of an understatement. The fund’s positions read like a pharmaceutical sales rep’s resume, with the top five positions, more than 50% of the entire portfolio, all coming from the biopharmaceutical sector. Mr. Edwards has no medical training and does not hold a degree in biology or chemistry. But more »
Peter Lynch, one of the most successful investors in the world, managed to grow Fidelity Magellan Fund from $20 million to around $14 billion from 1977 to 1990. He has delivered an unmatched investment performance of a 29% annualized return. He advised investors to know what they own, and spent a lot of time identify good businesses with good management.
In his book, “One Up On Wall Street”, he laid more »
- Page 1 of 3